Ouchi K, Takahashi S, Sasaki K, Yoshida Y, et al. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial. Int J Colorectal Dis 2024;39:89.
PMID: 38862615